Daily syntheses of primary biopharma news, stock indicators, volume anomalies, and market-moving events.
FDA approvals for Moderna's mRNA flu vaccine and Replimune's melanoma therapy headline today's harvest. IPO momentum continues (Attovia $289M, Braveheart $382M), while Supernus-Indivior and Tarsus-Alkeus deals, BioMarin's phase 3 miss, and an Alnylam earnings plunge round out a busy session.
Nineteen fresh items across 8 sources: Moderna's mRNA flu vaccine wins FDA approval, Braveheart and Tarsus make big market moves, LifeMine raises $263M, Emergent restructures, and the FDA approves the first full-spectrum narcolepsy Type 1 treatment.
Big pharma Q2 earnings dominate (Lilly's $23B beat, Novo's pipeline setbacks, Gilead's diversification push), Amgen trims an early obesity program, Supernus and Indivior agree to merge, the FDA approves Mucinex's first OTC cold-and-flu innovation in 14 years, and AI keeps moving into clinical development.
Sixteen fresh items across five sources today: Pfizer axes an ex-Metsera obesity asset, Merck logs a mid-stage win and miss from its Prometheus bet, KKR inks a $5.7B take-private of Integer, Latigo sets $247M IPO terms, Lisata cuts 72% of staff, and the Congo Ebola outbreak passes 1,700 deaths.
Supernus-Indivior $2.2B CNS merger, AZ-BMS merger talks per FT, Curium's ~$8B Lantheus buy, Lilly-Resilience $750M device investment, BlossomHill and Apnimed IPOs, Amgen cloud breach, and Novo's Phase 3 IL-6 setback headline the day.
Seven Endpoints News items covering Novo Nordisk's late-stage cardiovascular failure, AbbVie's Skyrizi-driven guidance raise, Moderna's norovirus readout delay, Alnylam's Q2 slump, the 340B rebate pilot, and pharma tariff timing.
48 articles from 7 sources covering FDA regulatory activity, corporate earnings, deal activity, and policy developments in biopharma.
Today's biopharma news cycle spans Apnimed's $192M IPO, Alnylam's full-year guidance cut, Replimune and Capricor adcomm fallout, Sanofi's pipeline concerns after weak Dupixent-dependent earnings, plus the FDA's first freeze-dried plasma product license. Sixty articles across ten sources.
44 fresh articles harvested across BioSpace, Endpoints, STAT and FDA Newsroom on 2026-07-30. Top clusters: Capricor/Replimune FDA adcomms (2 rejections), J&J-Sail $2.58B CAR-T option, Sanofi €1B write-off + new CEO R&D reset, AtaiBeckley pre-Lilly $2.8B deal context, and a wave of Q2 earnings across BMS/Regeneron/UCB/Ipsen.
Forty-three fresh articles from eleven sources on 2026-07-29, with Q2 earnings (Biogen, Leqembi), FDA actions (Replimune staff review, Hengrui citations, generic weight-loss guidance, Viatris contraceptive approval), and a fresh round of reverse-merger listings. Notable: J&J $5.5B talc proposal, Eli Lilly tops productivity ranking, Vertex pays AbCellera $28M for autoimmune TCE.
GSK's £2.5B three-year cost-saving plan dominated the trade-press conversation with five convergent headlines spanning mature-product targeting, R&D consolidation, and a £1.33B cough-trial write-down; Altimmune's GLP-1/GIP dual scored an 'unequivocal' Phase 2 in heavy drinking, opening the alcohol-use-disorder lane; Novo Holdings-backed Claris Bio and RA Capital-launched Oak Hill Bio each closed their debut rounds on the same morning; the FDA's July adcomm slate — Replimune, Capricor, six wellness peptides — previewed a busy late-summer advisory committee cycle; Outlook Therapeutics finally won FDA approval of Lytenava after three prior CRLs.
AstraZeneca led the day with three convergent signals — solid Q2, ADC pipeline discipline, and an AI-led late-stage trial strategy; Sarepta and Legend Biotech both announced abrupt CEO transitions; Argenx paid $2.2B for Forte Biosciences and its Phase 2 vitiligo candidate; the FDA recommitted to advisory committees while Dexcom became the first to join a new FDA/CMS health-tech pilot.
Today's harvest from BioSpace, Fierce Pharma, Fierce Biotech, and STAT News surfaces two Amgen stories (FDA appeal for Tavneos, ~40 layoffs) plus a Roche Q2 pipeline update from CEO Schinecker and a Fierce Biotech study flagging genetic risk markers in Yescarta patients.
Nineteen articles from 9 sources harvested between 2026-06-25 and 2026-07-25. Coverage clusters around FDA advisory panels (peptide compounding, Amgen's Tavneos defense), major oncology approvals (GSK's $10.6B bet), the Novo-Lilly ad-suit escalation, and Venus Medtech's trilingual TAVR enrollment milestone. The week's biggest missing beat: no AI-bio clinical readouts.
A daily synthesis of the 63 biopharma news items the OpenBio News harvest cron pulled this morning: Trump's renewed tariff threat on generic drugs not made in the US, FDA adcomm voting in favor of lifting restrictions on BPC-157, Scribe Therapeutics' $129M IPO, Lundbeck's Fast Track for an orexin-2 narcolepsy drug, Roche's FDA clearance for cobas BV/CV, FDA leadership transitions under the new commissioner, Repligen's $1.5B BioLife buy, and 18 newly-tagged mid-cap companies.
A daily synthesis of the 26 biopharma news items the OpenBio News harvest cron pulled this morning: FDA approval of Jideytro (zidesamtinib) for ROS1-positive NSCLC validating GSK's $10.6B Nuvalent acquisition, Lilly's triple-G agonist hitting 22% weight loss in Phase 3, J&J's bispecific combination delivering 89% PFS in multiple myeloma, Roche's late-stage pipeline confidence, Sanofi FDA untitled letter over Beyfortus, FDA TEMPO digital health pilot selection, Scancell/Neuphoria reverse merger, BeOne's $300M U.S. manufacturing expansion, and a Merck Ebola vaccine trial in the DRC.
Today's 49-article harvest covers Merck's oral PCSK9 launch, Lilly's $2.8B AtaiBeckley deal, Agios's sickle cell disappointment, FDA's PreCheck manufacturing pilot, and AstraZeneca's Wainua flop.
Today's harvest (32 new news files + 6 new company JSONs) covers five threads that stood out: Gilead + Merck's Phase 3 data backing a first weekly oral HIV pill, Agios dropping its next-gen sickle cell candidate, Samsung Biologics' $1.8B PolyPeptide buyout, a wave of US-biotech Hong Kong IPOs (Axiom), and the Novo-Lilly GLP-1 ad fight. FDA activity ran hot: 14 new CRLs released, a third rejection for Hengrui-Elevar's liver cancer combo, and the FDA's radical-transparency policy running into legal uncertainty. Smaller beats: Novartis geography-agnostic on China deals, Moderna-CureVac patent litigation, Scholar Rock's apitegromab site-classification wait, and Tempus AI's $1.5B Personalis buy. Tier 1 cron additions: jupiter-neurosciences, scholar-rock, legend-biotech, agios-pharmaceuticals, samsung-biologics, tempus-ai. STAT News and BioSpace both ran opinion pieces that the political-filter dropped at parse time.
Today's recovered batch (46 new news files, recovered from the 9 AM PT cron that aborted mid-write) covers three threads that stood out: Eli Lilly's $3.8B psychedelics move via AtaiBeckley, Samsung Biologics' $1.8B all-cash bid for PolyPeptide, and two parallel AI-supercomputer announcements (BMS with Nvidia, BMS-Nvidia separate coverage). Other themes: Novo's oral Wegovy cleared in the EU, Merck's oral PCSK9 (enlicitide) becoming the first oral option in the cholesterol-lowering PCSK9 class, German lawmakers' cost-savings bill that drugmakers warn will drive R&D out, FDA's CRL-release pause, the EU's Sanofi flu-vaccine antitrust probe, FDA's psychedelic-guidance finalization, and Camurus's CAM2029 NDA resubmission acceptance. Endpoints News contributed the largest share (15 articles) but with notable paywall filtering; STAT News's editorial surface ran warm on political/healthcare-policy commentary that the cron filtered at parse time per Rule 7.
Today's harvest (8 new news files + 1 new company JSON) is unusually thin on the heavy trade-press beats — Endpoints News contributed 16 candidates but every URL was gated by its soft paywall, and STAT News's editorial surface ran warm on politically charged healthcare items that the cron filtered out at parse time. The day's write-eligible set clusters on three narrower threads: a topical skin-closure product launch from BRIJ Medical (BRIJ-SEAL™), a small set of federal-healthcare / professional-society items (APhA's FDA comments on peptide substances, Presage's FedRAMP authorization via Kno2, Salus Scientific's burn-care consensus welcome), and two device-business items (Poriferous's DuraBloc patent, ANF Care's US wearable launch). One STAT international public-health story (WHO pressing Uganda on Marburg updates) and one borderline healthcare-policy item (Medicare smoking-cessation coverage expansion) round out the day.
Today's harvest (10 articles) clusters around three themes: a continued biotech IPO wave with Braveheart, Attovia, Vogenx, and BlossomHill pricing deals; the FDA's approval of the first oral PCSK9 inhibitor (Merck's Lipfendra / enlicitide) and the full approval of Novartis's Fabhalta in IgAN; and a pair of late-stage M&A developments — the Jasper Therapeutics all-stock merger with Kira Pharmaceuticals, and Eli Lilly's $2.8B acquisition of AtaiBeckley. Endpoints News contributed 20 candidates but every URL is gated by Endpoints' soft paywall; political/healthcare-policy items (transgender care, CDC confirmation, vaccine injury claims, China biotech restrictions, CMS GLOBE/GUARD litigation) were filtered at parse time.
GSK culls a $2B Bellus chronic-cough drug after Phase 3 failure; Celcuity's Revtorpyk wins FDA breast cancer approval; biotech IPO filings accelerate (Braveheart, Attovia, BlossomHill) and M&A stays heavy with Lilly's $2.8B AtaiBeckley psychedelics buyout and Dimerix's $292M Mission kidney deal.
A daily synthesis of the 39 biopharma news items the OpenBio News harvest cron pulled this morning: FDA approval of Merck's oral PCSK9 inhibitor Lipfendra, two parallel Lilly psychedelic buyouts (AtaiBeckley, ~$2.8-3.8B), projected 14,000+ H1 biopharma layoffs, Sanofi's mRNA-patent suit against Pfizer and Moderna, an FDA screwworm-drug EUA, and the Vogenx and Braveheart IPO filings.
45 news items harvested from 11 biopharma outlets, covering Kelun-Merck's NSCLC ADC win, biotech IPO momentum, Celcuity's breast-cancer approval, FDA CRL policy resumption, and Bora-Insilico's $2.5B AI partnership.
Today's harvest: 37 fresh news files. Dominant themes: large-pharma dealmaking (Vertex-Crinetics, AstraZeneca-Dizal, Spero-Innovent, Avere-Hansoh, Chai Discovery $400M); the AstraZeneca-Ionis Wainua Phase 3 cardiomyopathy failure landing on three sources; FDA simplification of pharmaceutical manufacturing and registration (three separate articles); FDA approval of Leqembi Iqlik SC starter dose (Biogen/Eisai); and FDA psychedelics guidance finalization. Endpoints News was fully soft-paywalled (28/28 rejected) for the fifth consecutive run; STAT ran political/feature content the editorial filter dropped.
Today's harvest landed 20 fresh news files across 7 sources. The dominant theme is regulatory and deal flow: FDA posted new CRLs days after pausing the disclosure program, Boehringer's nerandomilast (Jascayd) became Europe's first new IPF drug in years, Q32 Bio's anti-IL-7R antibody bempikibart jumped on Phase 2 alopecia data, and AstraZeneca's new Sino Biopharm COPD pact surfaced via MedCity News. Endpoints News was fully soft-paywalled and contributed zero articles this run despite 13 candidates. STAT News and Reuters Biopharma contributed only filtered-out items (political, op-ed, author name, general market).
Today's harvest: 1 fresh news file from BioSpace covering FDA's pause on public release of Complete Response Letters following an April citizen petition. Endpoints remained fully paywalled; STAT ran several politically charged pieces and healthcare-feature columns that the editorial filter dropped; prior-run coverage of AstraZeneca/Ionis/Wainua, Roche/Huntington's, and Bausch+Lomb/glaucoma topic clusters absorbed the remaining fresh candidates.
Today's harvest: 4 fresh news files spanning an FDA approval (Padcev-Keytruda in MIBC), a balance-sheet deal (Bayer-Apollo), a BioMarin patient-marketing push for PKU teens, and a Phase 3 ADC win for the GSK-Hansoh partnership in China. Endpoints soft-paywall and topic duplicates with prior coverage held the headline count down.
Today's harvest adds 26 free biopharma items across 6 sources, led by FDA/regulatory updates, clinical-development signals, China-linked partnerships, financing and M&A coverage, and selected company leadership or manufacturing moves.
56 fresh biopharma items across 7 sources (Endpoints News was fully soft-paywalled today so 37 of its candidates were dropped). BioPharma Dive contributed 17 of the 56 items including Roche KRAS head-to-head, Alkermes CEO succession, MeiraGTx/Oberland $400M financing, and Celea $180M IPF. FDA approvals landed for ENNUMO (Accord BioPharma), Theranica Nerivio coverage, WuXi Biologics PLI approval, and Vera Therapeutics atacicept for IgAN. Alector absorbed GSK's abandoned $700M Alzheimer's collab while Fate's off-the-shelf CAR-T prospect reported early promise in systemic sclerosis.
53 fresh biopharma items across 8 sources. Vertex's $10B Crinetics buy and a $400M MeiraGTx financing headline the day; FDA hands Vanda, Octapharma, and Porton Advanced multiple approval-track wins; Endpoints News is fully paywalled today so the major M&A and 340B stories landed only via Fierce Pharma and BioPharma Dive.
Today's harvest surfaced 3 articles after 30-day + URL-dedupe + political-deny + Tier-2 cross-site collapse. Headlines cluster around Endpoints' second-half M&A kickoff led by Novartis/Vertex/Ipsen with up to $12.6B in new deals on top of a 45-deal H1 2026, BioPharma Dive's coverage of Ipsen's Memo Therapeutics buyout as a rare-disease buildout, and MedCity News's angle on Novartis's Myricx ADC differentiation thesis.
Today's harvest across 11 biopharma news sources surfaced 8 articles after 30-day + URL-dedupe + political-deny + Tier-2 cross-site collapse. Headlines cluster around Novartis's $1.5B Myricx ADC deal, Genentech's 103-job layoff paired with a $490M Astex biobucks pact, Scribe Therapeutics' IPO signal, BridgeBio's Attruby kidney-benefit positioning, Movmedix's US FDA-cleared entry, Celea's $180M IPF pivotal funding, a 5-molecular-glue overview, and a BioSpace H1-2026 FDA retrospective.
Today's harvest across 11 biopharma news sources surfaced only one surviving article after filtering: a BioSpace recap of the BIO 2026 conference in San Diego noting the upbeat dealmaking and IPO sentiment, an evolving FDA posture, and a high-profile retraction of a pivotal study backing Amgen's rare-disease drug Tavneos.
Endpoints News dominates with 38 articles covering Scribe Therapeutics IPO filing, AstraZeneca's CSPC kidney drug deal, and Anthropic's Claude Science launch for pharma. Fierce Biotech contributes 10 articles including United Therapeutics' $140M thymic cell therapy acquisition and Roche's phase 3 lung cancer win.
Today's 50-article harvest clusters around four themes: FDA PreCheck pilot selections and cell/gene therapy approvals (Orca Tregzi, Vertex Casgevy pediatric label, 4DMedical TGA), M&A and licensing consolidation (Ipsen-Kartos, AbbVie-Apogee, Biogen-RayThera, AstraZeneca-CSPC, Theravance $929M buyout, Sixth Street/KKR-BridgeBio $1B), China-anchored deal flow (Pfizer-Innovent insurance, Lilly-Veropharm China, Drugmakers defend Chinese trials), and CDMO/careers signal (Lonza ADC expansion, Kimball EU/India build, 8 companies hiring in Greater Philadelphia). Notable absences: no STAT Plus pieces (paywall), zero FDA newsroom press announcements (all were older than 30 days), Endpoints coverage down to one (soft paywall) and MedCity down to three (anti-bot 403).
Today's harvest produced 46 fresh news files spanning Endpoints News, Reuters Biopharma, PRNewswire, BioSpace, and FDA Newsroom — anchored by FDA's pediatric sickle-cell gene-therapy approval, Roche's KRAS Phase 3 victory over Amgen/BMS, and BridgeBio's $1B launch fundraise, with 8 new company JSONs created.
Today's incremental harvest produced a single new article — BeOne's Brukinsa hitting its primary endpoint in a Phase 3 mantle-cell-lymphoma confirmatory trial — while 19 of 20 candidates were already represented in the news folder, reflecting a backlog-cleanup pattern with 20-article candidates against 1 truly new piece.
FDA PreCheck Pilot Program with Lilly and Regeneron headlined a heavy regulatory day; Sobi and Unicycive received new CRLs for contract manufacturing; Viridian's Lumvoa approved to challenge Amgen's Tepezza; Zymeworks to acquire Theravance for $929M.
Nine fresh items harvested from the four biopharma homepages on 2026-06-29, with M&A headlines (Zymeworks-Theravance, Ipsen-Kartos), a Sobi CRL on both Fierce Pharma and Endpoints, and a Viridian FDA approval / market debut dominating the cycle. Industry-volume is moderate, with FDA activity, M&A, and one clinical-failure news.
Five fresh items harvested from the four biopharma homepages on 2026-06-28, with FDA approvals and a CMO warning letter dominating the cycle. Industry-volume is light post-BIO 2026 and pre-Q2 earnings season.
A daily synthesis of the 10 biopharma news items the OpenBio News harvest cron pulled this morning: FDA advisory panel scheduling for Replimune and Capricor, a Viridian eye-drug approval framed as competition with Amgen's Tepezza, a SCOTUS Roundup ruling and its two-day aftermath, the GSK new-CEO buyout, Pfizer-Seagen cooling vs. a Pfizer-Innovent China pact, a 'historic' solid-tumor CAR-T nod, and an Ebola case count crossing 1,000 in Congo.